Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Long-Term Debt Repayments (2025)

Kezar Life Sciences (KZR) has disclosed Long-Term Debt Repayments for 1 consecutive years, with $6.7 million as the latest value for Q4 2025.

  • Quarterly Long-Term Debt Repayments changed N/A to $6.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.6 million through Dec 2025, changed N/A year-over-year, with the annual reading at $10.6 million for FY2025, N/A changed from the prior year.
  • Long-Term Debt Repayments hit $6.7 million in Q4 2025 for Kezar Life Sciences, up from $1.3 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $6.7 million in Q4 2025 to a low of $1.3 million in Q1 2025.